Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters.

Mycotoxin nivalenol (NIV) is a natural contaminant of various cereal crops, animal feed and processed grains throughout the world. Human and animal contamination occurs mainly orally, and the toxin must traverse the intestinal epithelial barrier before inducing potential health effects. In this study, we investigated the mechanisms involved in NIV transepithelial transfer. The human intestinal Caco-2 cell line showed a basal-to-apical polarized transport of NIV. Using metabolic inhibitors and temperature-dependent experiments, we demonstrated that basolateral-apical (BL-AP) transfer of NIV involved an energy-dependent transport whereas apical-basolateral (AP-BL) transfer was governed by passive diffusion. NIV efflux was significantly decreased in the presence of the P-glycoprotein (P-gp) inhibitor valspodar, the multi-drug resistance-associated proteins (MRPs) inhibitor MK571, but was not modified by the breast cancer resistance protein (BCRP) inhibitor Ko143. Intracellular NIV accumulation was investigated using epithelial cell lines transfected with either human P-glycoprotein or MRP2. This accumulation was significantly decreased in LLCPK1/MDR1 and MDCKII/MRP2 cells, compared to wild-type cells, and this effect was reversed by valspodar and MK571, respectively. These in vitro results suggested that NIV was a substrate for both P-glycoprotein and MRP2. This interaction may play a key role in weak intestinal absorption of NIV and the mainly predominant excretion of NIV in faeces in animal studies.

[1]  Y. Ueno.  Trichothecenes : chemical, biological, and toxicological aspects , 1983 .

[2]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[3]  S. Edwards,et al.  Influence of agricultural practices on fusarium infection of cereals and subsequent contamination of grain by trichothecene mycotoxins. , 2004, Toxicology letters.

[4]  J. D'mello,et al.  A review of worldwide contamination of cereal grains and animal feed with Fusarium mycotoxins , 1999 .

[5]  R. Schothorst,et al.  Report from SCOOP task 3.2.10 "collection of occurrence data of Fusarium toxins in food and assessment of dietary intake by the population of EU member states". Subtask: trichothecenes. , 2004, Toxicology letters.

[6]  M. Vore,et al.  Regulation of Expression of the Multidrug Resistance-Associated Protein 2 (MRP2) and Its Role in Drug Disposition , 2002, Journal of Pharmacology and Experimental Therapeutics.

[7]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[8]  C. Hsia,et al.  Nivalenol, a main Fusarium toxin in dietary foods from high-risk areas of cancer of esophagus and gastric cardia in China, induced benign and malignant tumors in mice. , 2004, Oncology reports.

[9]  Y. Sugita‐Konishi,et al.  The fates of trichothecene mycotoxins, nivalenol and fusarenon-X, in mice. , 2003, Toxicon : official journal of the International Society on Toxinology.

[10]  J. Fink-Gremmels,et al.  Ochratoxin A secretion by ATP-dependent membrane transporters in Caco-2 cells , 2006, Archives of Toxicology.

[11]  H. Pettersson,et al.  Effects on health and blood plasma parameters of laying hens by pure nivalenol in the diet. , 2002, Journal of animal physiology and animal nutrition.

[12]  J. Lindberg,et al.  Absorption and metabolism of nivalenol in pigs. , 1997, Archiv fur Tierernahrung.

[13]  M. Schollenberger,et al.  Natural Occurrence of 16 Fusarium Toxins in Grains and Feedstuffs of Plant Origin from Germany , 2005, Mycopathologia.

[14]  Y. Dohi,et al.  Deepoxynivalenol: a new metabolite of nivalenol found in the excreta of orally administered rats , 1989 .

[15]  T. Murakami,et al.  Expression and function of efflux drug transporters in the intestine. , 2006, Pharmacology & therapeutics.

[16]  Donald W. Miller,et al.  In vitro and in vivo models for assessing drug efflux transporter activity. , 2003, Advanced drug delivery reviews.

[17]  M. Morris,et al.  Transport of dietary phenethyl isothiocyanate is mediated by multidrug resistance protein 2 but not P-glycoprotein. , 2005, Biochemical pharmacology.

[18]  J. Pestka,et al.  Toxicology of deoxynivalenol (vomitoxin). , 1996, Journal of toxicology and environmental health.

[19]  A. Schinkel,et al.  Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.

[20]  K. Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport , 1996 .

[21]  C. Xia,et al.  EXPRESSION, LOCALIZATION, AND FUNCTIONAL CHARACTERISTICS OF BREAST CANCER RESISTANCE PROTEIN IN CACO-2 CELLS , 2005, Drug Metabolism and Disposition.

[22]  W. Rubas,et al.  A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and limitations of the Caco-2 model. , 1997, Critical reviews in therapeutic drug carrier systems.

[23]  Kristina Luthman,et al.  Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article: S0169-409X(96)00415-2. The article was originally published in Advanced Drug Delivery Reviews 22 (1996) 67–84.1 , 2001 .

[24]  Chow H Lee.  Reversing agents for ATP-binding cassette (ABC) transporters: application in modulating multidrug resistance (MDR). , 2004, Current medicinal chemistry. Anti-cancer agents.

[25]  H. Macdonald,et al.  Energy metabolism and T-cell-mediated cytolysis. I. Synergism between inhibitors of respiration and glycolysis , 1977, The Journal of experimental medicine.

[26]  L. Mayer,et al.  Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  J. Leblanc,et al.  Estimated dietary exposure to principal food mycotoxins from The First French Total Diet Study , 2005, Food additives and contaminants.

[28]  P Langguth,et al.  P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. , 1998, Journal of pharmaceutical sciences.

[29]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[30]  G. Szakács,et al.  MDR3 P-glycoprotein, a Phosphatidylcholine Translocase, Transports Several Cytotoxic Drugs and Directly Interacts with Drugs as Judged by Interference with Nucleotide Trapping* , 2000, The Journal of Biological Chemistry.

[31]  M. Kool,et al.  Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. , 1998, The Journal of clinical investigation.

[32]  V. Gekeler,et al.  The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. , 1995, Biochemical and biophysical research communications.

[33]  H. Pettersson,et al.  Lack of de-epoxidation of type B trichothecenes in incubates with human faeces , 2003, Food additives and contaminants.

[34]  Y. Schneider,et al.  Interaction of ochratoxin A with human intestinal Caco-2 cells: possible implication of a multidrug resistance-associated protein (MRP2). , 2003, Toxicology letters.

[35]  P. Artursson,et al.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. , 1991, Biochemical and biophysical research communications.

[36]  K. Ehrlich,et al.  Protein synthesis inhibition by 8-oxo-12,13-epoxytrichothecenes. , 1987, Biochimica et biophysica acta.

[37]  F. Raimondi,et al.  Absorption of fumonisin B1 and aminopentol on an in vitro model of intestinal epithelium; the role of P-glycoprotein. , 2005, Toxicon : official journal of the International Society on Toxinology.

[38]  K. Fukasaku,et al.  Fusarium poae and Fusarium crookwellense, Fungi Responsible for the Natural Occurrence of Nivalenol in Hokkaido , 1993, Applied and environmental microbiology.

[39]  P. Borst,et al.  Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. , 1995, The Journal of clinical investigation.

[40]  Patrick J. Sinko,et al.  Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells , 1998, Pharmaceutical Research.

[41]  Thomas J. Raub,et al.  Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.

[42]  C. Beglinger,et al.  Evidence for Different ABC-Transporters in Caco-2 Cells Modulating Drug Uptake , 1999, Pharmaceutical Research.

[43]  Ming Hu,et al.  Kinetic characterization of secretory transport of a new ciprofloxacin derivative (CNV97100) across Caco-2 cell monolayers. , 2002, Journal of pharmaceutical sciences.

[44]  M. Pinto,et al.  Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture , 1983 .

[45]  Y. Ueno,et al.  A survey of the occurrence of nivalenol, deoxynivalenol and zearalenone in food stuffs and health foods in Japan. , 1985, Food additives and contaminants.